Frontiers in Oncology (Mar 2024)

Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review

  • Yuxin Ma,
  • Xinhong Shi,
  • Kun Zhao,
  • Shuyi Hu,
  • Yue Shi,
  • Yingying Jiang,
  • Yiling Liu,
  • Lin Lu,
  • Yuting Chang,
  • Fei Zhou,
  • Yingying Dai,
  • Zipeng Wu,
  • Shiyi Li,
  • Zhiying Qian,
  • Xia Xu,
  • Chenchen Li,
  • Bo Shen,
  • Bo Shen,
  • Guoren Zhou,
  • Cheng Chen,
  • Xiaohua Wang,
  • Xiaohua Wang,
  • Jifeng Feng,
  • Jifeng Feng

DOI
https://doi.org/10.3389/fonc.2024.1328844
Journal volume & issue
Vol. 14

Abstract

Read online

Metastatic triple-negative breast cancer (mTNBC) has the worst prognosis among breast cancer subtypes. Immune checkpoint inhibitors (ICIs) plus chemotherapy have promising survival benefits. Herein, we report a 51-year-old woman whose metastatic lesions were diagnosed as triple-negative subtype and who received tislelizumab plus eribulin treatment and achieved excellent efficacy. To our knowledge, this study is the first attempt to present tislelizumab in combination with eribulin for mTNBC treatment. New treatments resulting in prolonged survival and durable clinical responses would benefit mTNBC patients. Then, we summarize the possible influencing factors of the interaction between tislelizumab and eribulin.

Keywords